-

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced that its application to transfer its securities to the Nasdaq Capital Market has been approved by Nasdaq Listing Qualifications. This transition allows IPA an additional 180-day compliance period, until August 18, 2025, to meet the minimum bid price requirement of $1.00 per share.

The Company's common stock will transfer from the Nasdaq Global Market to the Nasdaq Capital Market at the opening of business on February 21, 2025. This move is in accordance with Nasdaq’s Listing Rules and maintains IPA's listing while the Company continues executing its strategic initiatives.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is a biotherapeutic research and technology company specializing in AI-driven antibody discovery and development. Through its subsidiaries—including Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and ImmunoPrecise Antibodies (Europe) B.V.—IPA delivers an end-to-end solution for the development of next-generation antibody therapeutics. The company integrates systems biology, multi-omics modeling, and artificial intelligence to enable the discovery of highly specialized, fully human therapeutic antibodies tailored to challenging disease targets.

For more information, visit www.ipatherapeutics.com

Contacts

Investor Contact: investors@ipatherapeutics.com

Industry:

ImmunoPrecise Antibodies Ltd.

NASDAQ:IPA
Release Versions
EnglishFrench
$Cashtags
$IPA
$nvda
$xbi
Hashtags
#AI
#DrugDiscovery
#TechBio
#antibodies
#foundationai
#generativeai
#llm

Contacts

Investor Contact: investors@ipatherapeutics.com

Social Media Profiles
Linkedin
IPA on X
More News From ImmunoPrecise Antibodies Ltd.

MindWalk Holdings Corp. Announces Leadership Update

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced that Thomas Lynch, PhD, has departed the company and ceased to serve as Chief Business Officer, effective October 16, 2026. "We thank Thomas for his contributions to MindWalk and wish him well," said Jennifer Bath, PhD, Chief Executive Officer and President of MindWalk. "Our commercial priorities do not change. We have moved from building the technology to deploying it,...

MindWalk Screens 890,634 Antibody Sequences for Immune Risk in Under Five Hours

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today published a white paper showing that its LensAI™ immunogenicity screening ran across an entire public antibody database of 890,634 sequences in 4 hours and 41 minutes on Amazon EC2 Hpc8a instances powered by 5th Gen AMD EPYC™ processors, delivering up to 43% lower cost per sequence than a comparable Intel configuration running identical code. “Every antibody drug carries a questio...

MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies

BOSTON--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ: HYFT) (“MindWalk” or the “Company”), a Bio-Native AI company, today announced three senior appointments that strengthen its Boston-based development leadership as the Company’s pipeline advances toward preclinical efficacy studies. Zachary Maben, PhD, joins as Director, Antigen Discovery & Protein Engineering, from Arbor Biotechnologies and previously Pfizer. Joanne Lim, PhD, joins as Director, Preclinical Development, from Orum Ther...
Back to Newsroom